Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silence Therapeutics Plc ADR (NQ: SLN ) 19.65 +0.45 (+2.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Silence Therapeutics Plc ADR < Previous 1 2 Next > Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences August 27, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 15, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients June 27, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration June 24, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) June 20, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Present at Jefferies Global Healthcare Conference May 30, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress May 16, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference April 30, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors April 29, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) April 08, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights March 13, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) March 13, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024 February 28, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial February 23, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Oversubscribed $120 Million Private Placement February 05, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments December 01, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results November 14, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Present at Jefferies London Healthcare Conference November 08, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease November 01, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference September 26, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in September Investor Conferences September 06, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports Second Quarter 2023 Results August 16, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration July 11, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Present at the Jefferies Healthcare Conference May 31, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Reports First Quarter 2023 Results May 16, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration May 04, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events May 01, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference April 25, 2023 From Silence Therapeutics plc Via Business Wire Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera April 04, 2023 From Silence Therapeutics plc Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.